A review of national Veterans Health Administration data has identified how the number of glucose-lowering agents used prior to insulin initiation impacts glycemic control.
We examined the effect of country of origin on HBV testing and chronic HBV infection prevalence among APIs using data from Kaiser Permanente Hawaii.
When preventive care was exempt from the deductible, well-child visits did not change for children switching from traditional plans to high-deductible plans.
Cost display and cost charge induce different test ordering behavior depending on the healthcare setting.
This lifetime economic analysis demonstrates vagal nerve blocking therapy to be a cost-effective alternative to conventional therapy in class 2 and 3 obesity patients.
The previous issue of Evidence-Based Oncology (EBO) featured the first part of a condensed edition of a peer exchange on the future of immunotherapy in cancer care, which was convened by The American Journal of Managed Care. This edition of EBO features the rest of that exchange.
European Cancer Congress 2013
As clinical targets in more common malignancies emerge, testing and treatment options will increase. Balancing these choices with the high costs of new technology will be the challenge to ensure value in oncology care.
A disease management program for Medicare Advantage patients with diabetes and coronary artery disease resulted in significantly reduced hospital admissions and total healthcare costs.
In this retrospective study of patients with diabetes, adherent patients were more likely to achieve glycemic control than nonadherent patients.
Decreasing statin copayments because of the patent expiration of simvastatin has led to moderate increases in therapy adherence.